Crescent BiopharmaCBIO -5.11%10 Current Ratio is 13.78 as of Mar. 2026, which is 108% above its 10-year median of 6.63. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Crescent Biopharma ranks better than 84.77% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Crescent Biopharma's current ratio for the quarter that ended in Mar. 2026 was 13.78.
Crescent Biopharma has a current ratio of 13.78. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Crescent Biopharma's Current Ratio or its related term are showing as below:
CBIO'
s Current Ratio Range Over the Past 10 Years
Min: 3.62 Med: 6.63 Max: 13.78
Current: 13.78
During the past 2 years, Crescent Biopharma's highest Current Ratio was 13.78. The lowest was 3.62. And the median was 6.63.
CBIO's Current Ratio is ranked better than 84.77% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs CBIO: 13.78
Crescent Biopharma (NAS:CBIO) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Crescent Biopharma Current Ratio Related Terms
Crescent Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBIO vs KYTX, ZURA, ARVN: Current Ratio Comparison
For the Biotechnology subindustry, Crescent Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (CBIO) has a Current Ratio of 13.78 as of Mar. 2026. This is 108% above median its historical median of 6.63. Over the past decade, Crescent Biopharma's Current Ratio has ranged from 3.62 to 13.78. According to the industry distribution chart, Crescent Biopharma ranks #215 out of 1412 companies in the Biotechnology industry, placing it in the top 15.2%.
Is Crescent Biopharma's Current Ratio too high?
Crescent Biopharma's current Current Ratio of 13.78 is 108% above median its 10-year median of 6.63. Over the past 10 years, this metric has ranged from a low of 3.62 to a high of 13.78. The Biotechnology industry median Current Ratio is 3.90. Crescent Biopharma's value of 13.78 is 253.3% above this industry median. Based on the distribution chart, Crescent Biopharma ranks #215 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Current Ratio compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #215 out of 1412 companies for Current Ratio. This places Crescent Biopharma in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.90. Crescent Biopharma's value of 13.78 is 253.3% above this benchmark. Historically, Crescent Biopharma's own Current Ratio has ranged from 3.62 to 13.78 over the past decade. While the company's 10-year median is 6.63 vs. the industry median of 3.90, Crescent Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current Current Ratio of 13.78 is 253.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current Current Ratio is 13.78, which is 108% above median its own 10-year median of 6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Current Ratio of 13.78. The current Current Ratio is 13.78, which is 108% above median its 10-year median of 6.63 and 253.3% above the Biotechnology industry median of 3.90. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Current Ratio is 13.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for CBIO
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 